[Skip to Content]
[Skip to Content Landing]
Article
May 1992

Radiolabeled Antibody Therapy for Squamous Cell Carcinoma of the Head and Neck

Author Affiliations

From the Departments of Otolaryngology—Head and Neck Surgery (Drs Shikani and Richtsmeier) and Internal Medicine, Division of Radiation Oncology (Dr Klein and Mr Kopher), The Johns Hopkins Medical Institutions, Baltimore, Md.

Arch Otolaryngol Head Neck Surg. 1992;118(5):521-525. doi:10.1001/archotol.1992.01880050075018
Abstract

• Immunohistochemical staining for ferritin was performed on 11 human head and neck squamous cell carcinomas transplanted in nude mouse xenografts. Seven tumors were found to be positive. Using ferritin as a tumor antigen target, escalating doses of yttrium-90–labeled anti ferritin antibodies were injected intravascularly into nude mice that were transplanted with a ferritin-positive human squamous cell carcinoma. Forty-five days after injection, the mean treated tumor size was 25.6% of control in the 100-μCi group, and 20.6% of control in the 200-μCi group. Ninety days after injection the mean tumor size was 27.5% that of control in the 100-μCi group and 31.7% in the 200-μCi group. Higher doses of radiation (300 and 400 μCi per mouse) caused death of most of the animals due to radiation toxicity. Presensitization of the animal, before antibody injection, with a bolus intraperitoneal injection of 7.5 mg of cisplatin per kilogram of body weight, resulted in further reduction in tumor size when compared with antibody alone or cisplatin alone. This study demonstrates that radioimmunotherapy with selected doses of yttrium-90–labeled antiferritin antibodies is effective against human head and neck squamous cell carcinoma xenografts in nude mice.

(Arch Otolaryngol Head Neck Surg. 1992;118:521-525)

×